|
Accueil > Actualité
Sartorius Stedim: H1 EPS down 40%
(CercleFinance.com) - Sartorius Stedim Biotech has reported a 40.
4% drop in H1 2023 EPS at E2.62, with recurrent EBITDA of E415.7m, i.e. a margin of 29.7%, vs. 35.2% a year ago. The supplier of products and services to the pharmaceutical industry announced sales that are down 18.7% at E1.4bn, i.e. down 19.6% in organic terms at constant exchange rates, with an 18.5% decrease including acquisitions. Acknowledging that significant uncertainties surrounding the global political and economic situation remain, the group has nevertheless confirmed its FY sales and profitability forecasts. Copyright (c) 2023 CercleFinance.com. All rights reserved. |
11/12/2023 11:01
MaaT Pharmarésultats positifs dans les cancers du sang 11/12/2023 10:57 Exail Technologiescontrat dans le déminage terrestre 11/12/2023 10:41 Bristol Myersrésultats positifs autour du Breyanzi 11/12/2023 10:30 Rochede nouvelles données positives au congrès ASH 11/12/2023 10:20 Holcimreçoit deux prix lors de la COP28 11/12/2023 10:10 Pharnextle titre chute après une étude clinique décevante Tous les articles sociétés |
